Company’s 36-month beta value is 1.07.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TARS is 31.79M, and currently, short sellers hold a 30.44% ratio of that floaft. The average trading volume of TARS on October 30, 2024 was 698.40K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TARS) stock’s latest price update
Tarsus Pharmaceuticals Inc (NASDAQ: TARS)’s stock price has increased by 10.59 compared to its previous closing price of 39.67. However, the company has seen a 15.45% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-17 that Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids
TARS’s Market Performance
Tarsus Pharmaceuticals Inc (TARS) has seen a 15.45% rise in stock performance for the week, with a 33.38% gain in the past month and a 80.61% surge in the past quarter. The volatility ratio for the week is 7.67%, and the volatility levels for the past 30 days are at 5.31% for TARS. The simple moving average for the last 20 days is 19.80% for TARS stock, with a simple moving average of 39.49% for the last 200 days.
Analysts’ Opinion of TARS
Many brokerage firms have already submitted their reports for TARS stocks, with Goldman repeating the rating for TARS by listing it as a “Neutral.” The predicted price for TARS in the upcoming period, according to Goldman is $19 based on the research report published on November 20, 2023 of the previous year 2023.
William Blair, on the other hand, stated in their research note that they expect to see TARS reach a price target of $44. The rating they have provided for TARS stocks is “Outperform” according to the report published on July 18th, 2023.
TARS Trading at 33.91% from the 50-Day Moving Average
After a stumble in the market that brought TARS to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 3.22% of gains for the given period.
Volatility was left at 5.31%, however, over the last 30 days, the volatility rate increased by 7.67%, as shares surge +35.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +65.48% upper at present.
During the last 5 trading sessions, TARS rose by +15.45%, which changed the moving average for the period of 200-days by +98.51% in comparison to the 20-day moving average, which settled at $36.62. In addition, Tarsus Pharmaceuticals Inc saw 116.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TARS starting from LINK WILLIAM J PHD, who sale 35,000 shares at the price of $26.08 back on Aug 12 ’24. After this action, LINK WILLIAM J PHD now owns 0 shares of Tarsus Pharmaceuticals Inc, valued at $912,961 using the latest closing price.
FLYING L PARTNERS XI LLC, the Director of Tarsus Pharmaceuticals Inc, proposed sale 35,000 shares at $26.85 during a trade that took place back on Aug 12 ’24, which means that FLYING L PARTNERS XI LLC is holding shares at $939,750 based on the most recent closing price.
Stock Fundamentals for TARS
Current profitability levels for the company are sitting at:
- -1.88 for the present operating margin
- 0.93 for the gross margin
The net margin for Tarsus Pharmaceuticals Inc stands at -1.8. The total capital return value is set at -0.48. Equity return is now at value -75.04, with -53.05 for asset returns.
Based on Tarsus Pharmaceuticals Inc (TARS), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.72. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is -135.27.
Currently, EBITDA for the company is -142.28 million with net debt to EBITDA at 0.7. When we switch over and look at the enterprise to sales, we see a ratio of 18.71. The receivables turnover for the company is 2.7for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.03.
Conclusion
In a nutshell, Tarsus Pharmaceuticals Inc (TARS) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
